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Abstract
Anthelmintic drug resistance in livestock parasites is already widespread and in recent years there has been an increasing
level of anthelmintic drug selection pressure applied to parasitic nematode populations in humans leading to concerns
regarding the emergence of resistance. However, most parasitic nematodes, particularly those of humans, are difficult
experimental subjects making mechanistic studies of drug resistance extremely difficult. The small ruminant parasitic
nematode Haemonchus contortus is a more amenable model system to study many aspects of parasite biology and
investigate the basic mechanisms and genetics of anthelmintic drug resistance. Here we report the successful introgression
of ivermectin resistance genes from two independent ivermectin resistant strains, MHco4(WRS) and MHco10(CAVR), into the
susceptible genome reference strain MHco3(ISE) using a backcrossing approach. A panel of microsatellite markers were
used to monitor the procedure. We demonstrated that after four rounds of backcrossing, worms that were phenotypically
resistant to ivermectin had a similar genetic background to the susceptible reference strain based on the bulk genotyping
with 18 microsatellite loci and individual genotyping with a sub-panel of 9 microsatellite loci. In addition, a single marker,
Hcms8a20, showed evidence of genetic linkage to an ivermectin resistance-conferring locus providing a starting point for
more detailed studies of this genomic region to identify the causal mutation(s). This work presents a novel genetic approach
to study anthelmintic resistance and provides a ‘‘proof-of-concept’’ of the use of forward genetics in an important model
strongylid parasite of relevance to human hookworms. The resulting strains provide valuable resources for candidate gene
studies, whole genome approaches and for further genetic analysis to identify ivermectin resistance loci.
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Introduction
Parasitic nematode worms are important human and animal
pathogens. Human parasites infect well over 1 billion people
worldwide and livestock parasites cause major economic production
loss to grazing ruminants. Control is dependent on the use of a
limited number of anthelmintic drugs and intensive use of these has
already led to widespread resistance in livestock parasites [1–5]. In
recent years selection pressure has been applied to parasitic
nematode populations in humans by anthelmintic treatments used
in various control programs and, in the case of some filarial
nematodes, eradication programs [6]. In endemic regions, parasitic
nematodes often occur as mixed species infections and so the
application of drug treatments to control one parasite species
inevitably leads to selection pressure being applied to others.
Consequently, there is increasing concern about the development of
anthelmintic drug resistance in nematode parasites of humans.
Unfortunately, parasitic nematodes of humans make extremely
difficult experimental subjects and so there is a need to develop
model systems to study potential mechanisms of anthelmintic
resistance. Haemonchus contortus is a parasitic nematode of sheep
which has a high propensity to develop anthelmintic. It is also one
of the most amenable parasitic nematodes to experimental
manipulation which, together with recent progress in sequencing
its genome makes it a potentially powerful model system to study
drug resistance in the strongylid nematode group [7]. In addition,
genetic crossing is technically possible in this parasite and has
potentially powerful applications in the study of anthelmintic
resistance providing we can develop the necessary techniques and
resources [8–11].
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poorly understood. To date, most research has focussed on the
investigation of possible associations between the resistance
phenotype and polymorphisms in candidate genes. This approach
has been successful in identifying polymorphisms in the isotype-1
b-tubulin gene as important determinants of benzimidazole
resistance [12–13]. However, candidate gene studies have major
limitations and have yet to unequivocally identify molecular loci
responsible for resistance against other anthelmintic classes [14].
Genomic resources are improving for many parasitic nematodes,
including the production of high quality reference genome
sequences, which will allow the application of genome-wide
approaches that do not depend on prior assumptions regarding
potential resistance mechanisms [14–19]. However, the applica-
tion of such approaches is not likely to be a trivial task. Attempts to
associate specific genetic differences with a drug resistant
phenotype will be complicated by the high level of genetic
variation that often exists within and between parasitic nematode
populations [20–22]. Simple comparisons will potentially reveal
many genetic differences between drug resistant and susceptible
parasite strains that are not necessarily associated with anthel-
mintic resistance but with background genetic variation or with
other unrelated phenotypes. Consequently, there is a need to
develop experimental approaches to overcome these challenges.
The artificial selection of resistance by serial passage and
underdosing of susceptible laboratory strains has been undertaken
by a number of groups in the past ([23] in sheep, [24] in rodents
and [25–28] in vitro). However, a major limitation of such
approaches is that selection in the real world is very different to
that applied in the laboratory [20]. A more powerful approach is
to take strains of parasites in which resistance was originally
selected in the field and genetically map the anthelmintic
resistance loci. To undertake detailed genetic mapping, a number
of things are necessary. Firstly, the ability to undertake genetic
crossing in the organism. Secondly, to have characterised
genetically distinct (preferably isogenic) resistant and susceptible
isolates on which to undertake mapping crosses. Thirdly, a fully
sequenced and assembled genome (or at least a detailed genetic
map) for the organism. All of these are achievable for H. contortus
making genetic mapping in this organism a feasible objective in the
future [14]. However, a number of other genetic strategies which,
although short of classical genetic mapping, can potentially
improve our ability to use genome-wide approaches for the
identification of anthelmitic resistance genes in the short term.
One example of such an approach is the introgression of resistance
genes from field derived strains into a characterized susceptible
genetic background with repeated backcrossing. This would allow
whole genome or candidate gene comparisons such as transcrip-
tomics and genome-wide polymorphism analysis to be more
meaningfully applied and interpreted since differences between
backcrossed resistant strains and the susceptible parental isolate
would be limited to those regions of the genome linked to
resistance-conferring loci (Figure 1A).
In this paper we report the introgression of ivermectin
resistance-conferring loci from two different ivermectin resistant
strains, into the genetic background of the susceptible genome
reference strain MHco3(ISE) [29]. We have used microsatellite
markers to monitor the backcrossing and to genetically validate the
success of the approach. We also have preliminary evidence of
potential linkage of one marker to a resistance conferring locus.
This work provides an important proof of concept of this novel
genetic approach for parasites and has generated powerful tools to
investigate the genetic basis of ivermectin resistance.
Materials and Methods
Ethics statement
All experimental procedures described in this manuscript were
examined and approved by the Moredun Research Institute
Experiments and Ethics Committee and were conducted under
approved British Home Office licenses in accordance with the
Animals (Scientific Procedures) Act of 1986. The Home Office
licence number is PPL 60/03899 and experimental IDs for these
studies were E06/58, E06/75 and E09/36.
H. contortus strains
The MHco3(ISE) strain [29] is the product of multiple rounds
of inbreeding, is susceptible to all main classes of anthelmintics and
has been adopted as the standard genome strain for the H. contortus
sequencing project at the Wellcome Trust Sanger Institute (http://
www.sanger.ac.uk/Projects/H_contortus/). In spite of its inbreed-
ing history it retains high levels of genetic polymorphism [10,21].
The White River [30] and Chiswick avermectin resistant [31]
strains of H. contortus, were originally isolated from South Africa
and Australia respectively. Subsequently they have been experi-
mentally passaged through sheep for a number of years at the
Moredun Research Institute, and these versions of the strains are
designated as MHco4(WRS) and MHco10(CAVR) respectively
throughout the manuscript. These strains were chosen for this
work for several reasons: Firstly, their origins were from the field
and have subsequently been well characterized in the laboratory
[10,21,30,31] Secondly, we have previously shown that these are
genetically divergent with respect to the susceptible MHco3(ISE)
strain. This is important as it allows us to distinguish between
resistance and susceptible parental genotypes when genetic
markers are analyzed in the backcross progeny. Thirdly, they
were originally derived from different continents –MHco4(WRS)
from Africa and MHco10(CAVR) from Australia- and so it is
highly likely that ivermectin resistance has been independently
selected in each strain. This allows a potentially interesting
comparison of resistance mechanisms from two independently
selected strains.
Author Summary
The use of drugs (anthelmintics) to control nematode
parasites (roundworms) is common in both humans and
animals. This has led to the widespread development of
drug resistance in livestock parasites and serious concerns
regarding its emergence in human parasites. Haemonchus
contortus is a parasitic nematode of sheep that has a high
propensity to develop resistance and is the most widely
used model system in which to study anthelmintic drug
resistance. Ivermectin is an extremely important drug for
parasite control in both humans and animals. Here, we
report a novel approach using genetic crossing to transfer
a region of the H. contortus genome containing ivermectin
resistance genes from resistant strains into a susceptible
strain. During our backcrossing approach, we have
identified a genetic marker showing evidence of genetic
linkage to ivermectin resistance. The susceptible strain we
have used is currently having its complete genome
sequenced making the information and strains generated
here extremely valuable for the identification of ivermectin
resistance genes. This work represents an important proof
of concept for using genetic approaches to identify
genomic regions containing drug resistant genes in
parasitic nematodes.
Backcrossing Haemonchus contortus
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The basic approach was to cross male worms of the
MHco3(ISE) susceptible strain with female worms from the
resistant strains in the initial cross. Subsequently F1 female worms
derived from each generation of backcross were crossed again with
male MHco3(ISE) worms (Figure 1B). The F1 progeny of the first
genetic crosses between MHco3(ISE) and the two ivermectin
resistant strains MHco4(WRS) and MHco10(CAVR) were desig-
nated as MHco3/4 and MHco3/10 respectively. The nomencla-
ture for subsequent backcrosses was MHco3/4.BCn and MHco3/
10.BCn, denoting the Moredun Research Institute (M), H. contortus
(Hco), the unique numbers allocated to both parental strains (3/4
or 3/10), and the backcross generation (BC2, 3 and 4) (Figure 1).
Progeny of each cross were collected and cultured to L3 in the
standard way. They were then used to infect donor sheep to
generate L4 worms for the next backcross. These donor sheep
were treated with ivermectin to ensure only worms which were
phenotypically ivermectin resistant were used in the next backcross
(see following section for details). The passage of these larvae
through three more rounds of ivermectin selection and crossing
against the ivermectin susceptible isolate (MHco3(ISE)) produced
a final fourth backcross generation (MHco3/4.BC4 or MHco3/
10.BC4) (Figure 1B).
Harvesting and preparation of L4 worms for surgical
transplantation
Crosses between two strains were performed by surgically
transplanting approximately 50 late L4 male worms from one
strain and 50 late L4/adult female worms from the other strain
directly into the abomasum of a recipient sheep. In order to
produce L4 for transplantation male worm-free donor lambs were
orally dosed with between 5,000–10,000 L3 of either MHco3(ISE),
or the ivermectin resistant strain to be crossed against. H. contortus
donors with the ivermectin resistant strains were treated with
0.1 mg/kg of ivermectin (Oramec drench for sheep; Merial) on
day 10 or 11 post infection to select for ivermectin resistant
progeny prior to transplantation. Donor sheep were euthanased
on day 14 post infection and worms were harvested from their
abomasa (day 14 female worms of these strains have previously
been shown to be sexually immature and not produce viable
progeny; [32]). The abomasal contents and washings containing
the nematodes were first passed through a 1 mm sieve, transferred
into fresh physiological saline (0.85% NaCl) and then maintained
at 37uC. Male and female H. contortus could then be picked into
pre-warmed petri-dishes containing RPMI 1640 tissue culture
medium in readiness for surgical transfer into the abomasa of
worm-free recipient sheep. 45–100 male late L4/immature adult
MHco3(ISE) H. contortus and 50–100 female late L4/immature
adult H. contortus were surgically transferred into the abomasa of
male worm free recipient lambs, within 2 hours of recovery from
the donor sheep.
Setting up genetic crosses by surgical transplantation
Recipient sheep were anaesthetised to allow a 10 cm vertical
incision to be made through the skin, underlying fascia, muscle and
peritoneum, over the right flank, midway between the last rib and
pelvis and about 10 cm above the midline. The abomasum was
located and partially exteriorised, to enable a 1 cm diameter sub-
serosal purse-string suture to be placed. A stab incision was then
made in the centre of the purse-string suture, through which 50
male late L4/immature adult MHco3(ISE) H. contortus and 50
female late L4/immature adult MHco4(WRS), or MHco10(CAVR)
Figure 1. Backcrossing approach to introgress ivermectin resistance-conferring genes from resistance strains into the MHco3(ISE)
genetic background. Diagrammatic representation of overall backcrossing scheme (A). Schematic representation of experimental aim and
summary of nomenclature used (B). Genome of the MHco4(WRS) ivermectin resistant strain represented in red and the genome of the MHco3(ISE)
susceptible reference strain represented in blue.
doi:10.1371/journal.ppat.1002534.g001
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into the abomasum in approx 5 ml RPMI, using a 5 mm diameter
blunt ended, glass pipette. The purse-string suture was then closed
and the surgical incision repaired allowing the completion of
surgical transfers within about 2 hours from the recovery of the
nematodes from the donor sheep. Sheep were routinely injected
with 1 mg/kg meloxicam (Metacam 20 mg/ml solution for
injection; Boehringer Ingelheim) for post-surgical analgesia and
7 mg/kg amoxicillin/1.75 mg/kg clavulanic acid (Synulox ready-
to-use injection; Pfizer) and closely monitored on completion of the
surgery. No adverse effects were noted during the course of this
study. Eggs were identified in the faeces approx 3 days post surgery
and collected daily and coprocultured to produce L3.
Controlled efficacy test to determine ivermectin
sensitivity of backcross strains
A controlled efficacy test (CET) using ivermectin was under-
taken on the two separate fourth generation backcross strains,
MHco3/4.BC4, and MHco3/10.BC4 alongside the three original
parental strains used in this study, namely MHco3(ISE),
MHco4(WRS) and MHco10(CAVR). Seventy-five parasite naı ¨ve
lambs were divided equally between the five different strains. For
each strain, the 15 lambs were further allocated into three
treatment groups of five animals: no treatment, ivermectin
(0.2 mg/kg BW) or ivermectin (0.1 mg/kg BW). Lambs were
initially allocated randomly to strain and treatment groupings that
were subsequently balanced, where needed on the basis of sex and
the weight of the animal just prior to the experiment, to ensure
that groups were as similar as possible. The lambs were infected
with 5,000 H. contortus L3 on day 0. Faecal worm egg counts (FEC)
were conducted [33] at the start of the controlled efficacy test to
confirm their parasitic nematode-free status and on days 16, 18,
21, 28, 29 and 36 pi to monitor the counts. On day 29 post
infection (pi) the lambs were weighed again and orally dosed
where appropriate with the correct volume of ivermectin (Oramec
drench for sheep; Merial) using a syringe [34]. All of the lambs
were euthanased on day 36pi and worms harvested from their
abomasa for determination of H. contortus burdens in abomasal
saline washings and digests [34–35]. H. contortus recovered from
2% (MHco4 and MHco10) and 10% (MHco3, MHco3/4.BC4
and MHco3/10.BC4) sub-samples of the abomasal washings and
digests were counted and sexed (only adults were seen), the higher
sub-sample volume was examined in the backcross strains due to
the smaller numbers of worms present. The percentage efficacies
of each anthelmintic treatment were calculated using the equation
100 (12T/C), where T and C are the arithmetic mean total H.
contortus burdens of the treated and control groups respectively
[36]. The same equation 100 (12T/C) was also used for the
calculation of percentage treatment efficacy using faecal egg
counts of treated and control groups that were taken 7 days post
treatment, on day 36pi at necropsy. For all estimates of efficacy
95% confidence intervals (CIs) were calculated [36] and
anthelmintic resistance was deemed to be present when the
percentage efficacy of reduction of parasitic nematode burdens or
FECs was less than 95% [37]. In addition, the mean treatment and
upper and lower 95% confidence intervals were calculated on the
FEC data using Bootstrap analysis and a resampling number of
2000 using the ‘‘BootStreat’’ program [38] cited in [39].
Molecular genotyping and genetic analysis
All microsatellite genotyping, on both bulk and single worm
DNA lysates, was performed using the same PCR amplification
methods and parameters previously described [21]. Capillary
electrophoresis was performed using an ABI Prism 3100 genetic
analyzer (Applied Biosystems, Foster City, CA) for the accurate
sizing of microsatellite PCR products. The forward primer of each
microsatellite primer pair was 59-end labeled with FAM, HEX, or
NED fluorescent dyes (MWG) and electrophoresed with GeneS-
can ROX 400 (Applied Biosystems) internal size standard.
Individual chromatograms were analyzed using Genemapper
Software Version 4.0 (Applied Biosystems).
Bulk worm DNA lysates were made as previously described
[21]. Duplicate bulk lysates were made using approximately 500
L3 worms from each generation of the backcrossing procedure
(BC1,B C 2,B C 3,B C 4), the F1 progeny of the initial genetic crosses
(MHco3/4 and MHco3/10) and L3 from the three parental strains
MHco3(ISE), MHco4(WRS) and MHco10(CAVR).
In addition to the bulk worm DNA preparations, 30–40
individual (L3 or adult) worm DNA lysates were prepared from
seven strains for more detailed genetic analysis: the three parental
strains MHco3(ISE), MHco4(WRS) and MHco10(CAVR); the
two backcross strains, MHco3/4.BC4 and MHco3/10.BC4 and
the two populations of survivors (0.1 mg/kg ivermectin) of both
the backcross strains (taken from appropriate control and the
ivermectin treated animals from the controlled efficacy test
experiment respectively).
The genotyping of parasite populations/strains by amplifying a
microsatellite from ‘‘bulk’’ DNA lysates made from a population of
worms has been previously described [21]. It is a valuable
approach to quickly ‘‘fingerprint’’ worm populations for the
presence or absence of microsatellite alleles and gives an
approximation as to their relative frequencies. 18 microsatellite
loci were used for genotyping the bulk worm DNA lysates. These
included 13 previously well characterised loci: Hcms25, Hcms27,
Hcms33, Hcms36, Hcms40 [40]; Hcms8a20, Hcms22co3 [21];
HcmsX142, HcmsX146, HcmsX151, HcmsX182, HcmsX256,
HcmsX337 [10] and five new loci Hcms3561, Hcms18210,
Hcms26981, Hcms40506, Hcms18188 (Supplementary Table S1).
Nine microsatellite loci, chosen for their ability to differentiate
between the three parental strains, were used to genotype the
individual worm lysates from the seven key H. contortus strains.
These were Hcms27, Hcms36, Hcms40, Hcms8a20, Hcms22c03
and four recently identified loci, namely, Hcms3086, Hcms22193,
Hcms44104 and Hcms53265 (Redman et al., in preparation).
For the single worm genotype data, Pairwise FST values were
calculated using Arlequin version 3.11 [41]. Data were defined as
‘‘standard’’ rather than microsatellite, as it did not necessarily
adhere to stepwise mutation model. PCA was performed using
GenAlEx version 6 [42] preserving individual worm genotypes.
Results
Phenotypic analysis of parental and backcross
populations
The percentage efficacy of ivermectin at doses 0.1 mg/kg and
0.2 mg/kg was determined from H. contortus arithmetic mean
burdens of treated and control groups (Supplementary Figure S1).
Ivermectin efficacies were 100, 91, 78, 22 and 18% at 0.1 mg/kg
and 100, 90, 94, 38 and 50% at 0.2 mg/kg against the
MHco3(ISE), MHco3/10.BC4, MHco3/4.BC4, MHco10(CAVR)
and MHco4(WRS) strains respectively (Figure 2 and Supplemen-
tary Table S2). Hence, the resistance phenotypes of the parental
strains MHco4(WRS) and MHco10(CAVR) was confirmed as was
the presence of resistant parasites in the backcross populations
MHco3/10.BC4, MHco3/4.BC4.
Treatment efficacies based on faecal egg count reduction for the
MHco3(ISE), MHco3/10.BC4, MHco3/4.BC4, MHco10(CAVR)
and MHco4(WRS) strains were 100, 89, 69, 41 and 0% at 0.1 mg/
Backcrossing Haemonchus contortus
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respectively when compared to untreated controls (Supplementary
Table S3).
Monitoring the backcrossing procedure by microsatellite
genotyping of bulk worm DNA preparations
The genotyping of parasite populations/strains by amplifying a
microsatellite from ‘‘bulk’’ DNA lysates made from a population of
worms has been previously described [21]. Although, this
technique cannot give accurate allele frequency data for alleles
present at low frequency in the parasite population, it is a rapid
approach to ‘‘fingerprint’’ worm populations for the presence or
absence of microsatellite alleles and to obtain approximate
frequencies for the predominant alleles. Consequently, we used
this as a means of monitoring the backcrossing procedure as it
progressed. The alleles from all 18 microsatellite loci were scored
as either being ‘present’ or ‘absent’ in genotypes derived from the
bulk DNA lysate preparations of the parental isolate, the F1 strains
and each backcross generation (Supplementary Table S4 and S5).
When the parental strains MHco3(ISE) and MHco4(WRS) are
compared, a total of 17 different isolate-specific alleles were
identified across 9 different loci: 5 alleles present in MHco3(ISE)
but absent from MHco4(WRS) and 12 alleles present in
MHco4(WRS) but absent from MHco3(ISE). Similarly, compar-
ison of the parental strains MHco3(ISE) and MHco10(CAVR)
revealed a total of 41 isolate-specific alleles across 16 loci: 19 alleles
present in MHco3(ISE) but absent from MHco10(CAVR) and 22
alleles present in MHco10(CAVR) but absent from MHco3(ISE).
This is consistent with our previous report that both ivermectin
resistant strains are genetically distinct from the MHco3(ISE)
susceptible reference strain with MHco10(CAVR) being more
genetically divergent than MHco4(WRS) [10,21]. For both
backcrosses, almost all MHco3(ISE) specific alleles were main-
tained through the 4 backcross generations and were still present
in the MHco3/4BC4 and MHco3/10BC4 strains. The only
exceptions were the Hcms25, 215 bp and 217 bp alleles which
were present in the first backcross strain (MHco3/10.BC1) but
were lost at the second backcross generation (MHco3/10.BC2).
These were relatively rare alleles in MHco3(ISE) strain - allele
215 bp present at 3.6% and allele 217 bp present at 11.1% - and
therefore their loss could be due to purely stochastic reasons. In
contrast, almost all alleles specific to the two ivermectin-resistant
strains MHco4(WRS) or MHc010(CAVR), disappear during the
backcross procedure and are absent in the MHco3/4BC4 and
MHco3/10BC4 strains. There are only two exceptions to this.
First, the HcX256 allele 243 bp, which is retained in MHco3/
10BC4. However, it was only detected at a frequency of 4.6% in
MHco3/10BC4 compared with its original frequency of 38% in
the MHco10(CAVR) parental strain and so although not
completely eliminated, this allele has undergone a dramatic
reduction in frequency during the backcrossing procedure
(Supplementary Figure S2). The second exception is the
MHco10(CAVR)-specific alleles, 244 bp and 248 bp and the
MHco4(WRS)-specific allele 244 bp of loci Hcms8a20. These are
maintained throughout all generations of both backcrosses and this
is presented in more detail in the following sections. However,
overall the MHco3/4.BC4 and MHco3/10BC4 strains have a
similar genetic background to the MHco3(ISE) parental strain
based on bulk genotyping with a panel of 18 microsatellite loci as
would be predicted from the backcrossing scheme.
Genetic analysis by individual genotyping of parental
and backcrossed strains
The parental strains and final backcross populations (MHco3/
4.BC4 and MHco3/10.BC4) were analysed in more detail by
genotyping 30–40 individual worms with 9 of the most
discriminatory microsatellite markers (Figure 3). The data is
presented separately with marker Hcms8a20 either excluded (8
loci data) or included (9 loci data) since this marker shows evidence
of an association with the ivermectin resistance phenotype (see
next section). Pairwise FST estimates based on the multi-locus
genotype data revealed a high level of genetic differentiation
between the parental strains: MHco3(ISE) and MHco4(WRS) had
a high level of genetic differentiation (8 loci FST=0.2101, 9 loci
FST=0.2044, Figure 3A) and MHco3(ISE) and MHco10(CAVR)
an even higher level (8 loci FST=0.4146, 9 loci FST=0.4006,
Figure 3D). Hence MHco10(CAVR) is slightly more divergent
from MHco3(ISE) than is MHco4(WRS) confirming previous
comparative analysis of these strains [21]. This genetic differen-
tiation between the parental strains was also demonstrated by
principal component analysis of individual worm multi-locus
genotypes (Figure 3B, C, E and F). Both of the ivermectin resistant
strains ((MHco4(WRS) and MHco10(CAVR)) form clusters
distinct from the MHco3(ISE) cluster.
Both the BC4 backcross strains show a very low level of genetic
differentiation from the MHco3(ISE) parental strain (8 loci
FST=0.0299and9lociF ST=0.0265 for MHco3/4.BC4 and 8 loci
FST=0.0045and9lociFST0.0040forMHco3/10.BC4).Incontrast
they show a high level of genetic differentiation from the iver-
mectin resistant parental isolates (8 loci FST=0.1930 and 9 loci
FST=0.1767 between MHco4(WRS) and MHco3/4.BC4
(Figure 3A) and 8 loci FST of 0.3821 and 9 loci FST of 0.3657
Figure 2. Efficacy of ivermectin against H. contortus parental and backcross strains resulting from controlled efficacy experiment.
Percentage efficacies of ivermectin at two different therapeutic doses (0.1 mg/kg and 0.2 mg/kg) against the three parental strains and the backcross
strains, estimated by comparison of mean worm burden of treatment and control group. Y-error bars represent 95% confidence intervals.
doi:10.1371/journal.ppat.1002534.g002
Backcrossing Haemonchus contortus
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Indeed, this level of genetic differentiation is of a similar magnitude
as that seen between the original parental strain of each cross. These
results are again supported by the principal component analysis of
multi-locus genotypes of single worms where both the MHco3/
4.BC4 and MHco3/10.BC4 populations are distinct from the
MHco4(WRS) and MHco10(CAVR) strains respectively and cluster
with the MHco3(ISE) strain (Figure 3B, C, E and F). This
demonstratesthe geneticbackgroundofthe 4
thgenerationbackcross
strains is similar to that of the MHco3(ISE) parental strain.
Genetic analysis of worms from MHco3/4.BC4 and
MHco3/10.BC4 backcross strains that are phenotypically
resistant to ivermectin
Although the MHco3/4.BC4 and MHco3/10.BC4 backcross
populations are ivermectin resistant based on the CET, they are
significantly less resistant than the original MHco4(WRS) and
MHco10(CAVR) parental strains. This is not unexpected given
the nature of the backcrossing scheme (see discussion below) and
means the backcross strains consist of a mixed population of
worms of differing ivermectin resistant phenotypes. In order to
genetically characterize those worms that were phenotypically
resistant to ivermectin at a dose which is 100% effective for the
MHco3(ISE) isolate, we infected two sheep each with MHco3/
4.BC4 and MHco3/10.BC4, treated with 0.1 mg/kg and harvest-
ed and prepared DNA from adult worms that survived this drug
treatment. These worms surviving ivermectin treatment were then
individually genotyped with the 9 microsatellite markers and FST
and PCA analysis was performed initially with 8 loci (loci
Hcms8a20 excluded) and subsequently with loci Hcms8a20
included in the analysis (9 loci) (Figure 3). On the basis of the
eight markers, the ivermectin resistant individuals within the
MHco3/4 backcross strain were genetically very closely related to
the parental susceptible MHco3(ISE) strain, (8 loci FST=0.0379)
Figure 3. Visualisation of genetic differentiation between H. contortus parental and backcross strains. Pairwise FST estimates and
principal component analysis of parental and 4
th generation backcross isolates pre and post ivermectin treatment (0.1 mg/kg ivermectin) using multi-
locus genotype data. Figure 3A, B and C shows the data for the MHco3/4 cross and Figure 3D, E and F for the MHco3/10 cross. Both FST and PCA
analysis was performed with 9 loci and also with 8 loci (when Hcms8a20 was excluded from this latter analysis, since it shows evidence of genetic
linkage to the ivermectin resistance phenotype). Figure A and D show pairwise FST estimates: values in the tables below the diagonal are for analysis
of all 9 loci and above the diagonal for the 8 loci (excluding Hcms8a20). Genetic differentiation between isolates at significance level, p,0.01
(highlighted in bold and italics). Asterisk indicates level of genetic differentiation is marginal (significance at p,0.05). PCA analysis for all 8 loci are
shown in panels B and E and for the 9 loci (including 8a20) in panels C and F. Each data point represents a single worm based on a multi-locus
genotype of 9 or 8 markers.
doi:10.1371/journal.ppat.1002534.g003
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strain (8 loci FST of 0.2195 for MHco4(WRS)) (Figure 3A).
Similarly, the phenotypically ivermectin resistant worms within the
MHco3/10.BC4 were more genetically similar to the MHco3(ISE)
parental strain (8 loci FST=0.0181) than to the MHco10(CAVR)
parental strain (8 loci FST=0.3927) (Figure 3D).
Inclusion of the Hcms8a20 locus into the analysis produced a
similar result but slightly reduced the overall genetic differentiation
between the ivermectin resistant backcross worms from each of the
resistant parental strains (9 loci FST=0.2137 vs 8 loci FST=0.2195
between the MHco3/4.BC4 ivermectin survivors and
MHco4(WRS) strain and 9 loci FST=0.3647 vs 8 loci
FST=0.3927 between MHco3/10.BC4 ivermectin survivors and
MHco10(CAVR) (Figure 3A and D)). Conversely, inclusion of the
Hcms8a20 locus increases the genetic differentiation between the
ivermectin resistant backcross survivors and the susceptible
MHco3(ISE) parental strain to a point where it is statistically
significant: 9 loci FST=0.0487 vs 8 loci FST=0.0379 between the
MHco3/4.BC4 ivermectin survivors and MHco3(ISE) and 9 loci
FST=0.1129 vs 8 loci FST=0.0181 between the MHco3/10.BC4
ivermectin survivors and MHco3(ISE) (Figure 3A and D;
statistically significant genetic differentiation between any pair of
strains highlighted in italics).
Evidence of linkage of marker Hcms8a20 to an ivermectin
resistance-conferring locus
Consistent with the PCA and FST analysis, examination of the
allele frequency data derived from the single worm genotyping
revealed that for eight of the nine markers, the allele frequency
histograms of the ivermectin treatment survivors of strains MHco3/
4.BC4 and MHco3/10.BC4 were very similar to the MHco3(ISE)
susceptible parental strain and divergent from the resistant parental
strains MHc04(WRS) and MHco10(CAVR) respectively (see
Supplementary Figure S3A–H). However, this was not the case
for Hcms8a20. In this case, for both backcross strains, an allele that
was frequent in the resistant parental strain was retained in the
fourth generation backcross strains (Supplementary Table S4, S5
and Figure 4). In the case of the MHco3/4 backcross, allele 244 bp
(which was specific to the MHco4(WRS) parent) was retained at a
frequencyof8%intheMHc3/4.BC4worms.Notablythisincreased
to a frequency of 40% in the population of MHc3/4.BC4 worms
that survived 0.1 mg.kg ivermectin treatment (Figure 4). Similarly,
for the MHco3/10 backcross, allele 248 bp (which was specific to
the MHco10(CAVR) parent) was retained at a frequency of 12% in
MHco3/10.BC4 worms. Again, this increased to a frequency of
78% in the MHco3/10.BC4 worms that survived 0.1 mg/kg
ivermectin treatment (Figure 4).
Discussion
Introgression of ivermectin resistance genes into the
MHco3(ISE) susceptible genome reference strain
H. contortus is one of the few parasitic nematodes where genetic
crosses are currently possible. Previous genetic crossing experiments
have been performed to assess the level of dominance of resistance
genes and test for evidence of linkage of a P-glycoprotein with the
ivermectin resistance phenotype [9,11,43–45]. More recently, a
genetic mapping approach was undertaken in which resistant F2
were selected and AFLP used to look for markers associated with
resistance [8]. This was a potentially powerful approach although,
in that case, the ability to analyze the F2 progeny was limited by the
lack of genetic differentiation of the parental strains used. We have
taken a different genetic approach in which we have successfully
introgressed regions of the H. contortus genome containing loci
conferring ivermectin resistance from two different ivermectin
resistant strains into the genetic background of the MHco3(ISE)
susceptible strain. This latter strain is susceptible to the main classes
of anthelmintics and is currently being used as the reference strain
for the H. contortus genome sequencing project (http://www.sanger.
ac.uk/resources/downloads/helminths/haemonchus-contortus.html).
The introgression of resistance genes into this strain was achieved
by repeated backcrossing of the MHco4(WRS) and MHco10(-
CAVR) strains against the MHco3(ISE) strain with the applica-
tion of ivermectin selection at each backcross. A therapeutic dose
of 0.1 mg/kg ivermectin was chosen as an appropriate discrim-
inatory dose for selection because it is 100% effective against the
parental MHco3(ISE) strain (F. Jackson, unpublished data). This
was confirmed by our controlled efficacy test; not a single worm
of the MHco3(ISE) strain could be found surviving treatment at
this dose rate in any of the five treated sheep (Supplementary
Figure S1). In contrast, for both the backcross isolates MHco3/
4.BC4 and MHco3/10.BC4, a proportion of worms survived
ivermectin treatment at dose both the 0.1 and 0.2 mg/kg BW
dose rates demonstrating these surviving individuals were
phenotypically resistant to ivermectin.
Although both backcross strains contained individuals that were
phenotypically resistant to ivermectin treatment at doses 0.1 and
0.2 mg/kg, the overall resistance level of the backcross strains was
significantly lower than either of the parental resistant strains. This
is unsurprising given the nature of the backcrossing regime and
experimental design: In order to produce enough infective larvae
to undertake a controlled efficacy test, the F1 progeny of the fourth
backcross were used to infect a donor sheep which was not treated
with drug. Since any resistance alleles would be heterozygous in
the F1 of the fourth backcross, resistance alleles would segregate
during sexual reproduction of the worms in the final donor sheep
that was used to produce L3 for the CET. Hence, the final
backcross populations used in the CET would consist of a mixture
of resistant and susceptible worms. The relatively low proportion
of individual backcrossed worms with an ivermectin resistant
Figure 4. Allele frequencies of locus Hcms8a20 for H. contortus
parental and backcross strains. Allele frequencies based on
genotyping individual worms (parental strains, n=30; the 4
th genera-
tion backcross strains: MHco3/4.BC4, n=35 and MHco3/10.BC4, n=38;
and 4
th backcross generation survivors of ivermectin treatment at
0.1 mg/kg ivermectin: MHco3/4.BC4.survivors, n=33 and MHco3/
10.BC4.survivors, n=26). Asterisk indicates MHco4(WRS) and MHco10
(CAVR)-specific alleles retained in the backcross strains.
doi:10.1371/journal.ppat.1002534.g004
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multiple additive loci contribute to ivermectin resistance since only
those worms in which several resistance loci have segregated
would be resistant to the doses of drug used. Of course, different
alleles can differ in their magnitude of effect, their level of
dominance and their expressivity and so the overall relationship
between genotype and phenotype is potentially complex.
The important point is that backcross strains contain a
proportion of individuals that are phenotypically resistant to
ivermectin (unlike the MHco3(ISE) parental susceptible strain).
The observation that some worms in the backcross strains survive
treatment at this dose demonstrates that the resistance-conferring
alleles have been successfully introgressed from the parental
ivermectin resistant isolates MHco4(WRS) and MHco10(CAVR).
Importantly, when individual worms from the MHco3/4.BC4 and
MHco3/10.BC4 backcross strains that survive the 0.1 mg/kg
ivermectin treatment were genotyped with our microsatellite
markers, their genetic background was very similar to that of the
susceptible MHco3(ISE) parental strain and highly differentiated
from the MHco4(WRS) and MHco10(CAVR) resistant parental
strains (Figure 3). This demonstrates that these individuals contain
resistance-conferring loci, derived from the resistant parental
strains, but have a MHco3(ISE) susceptible genetic background
across most of the genome. Hence these strains now provide a
powerful resource on which to apply functional genomic strategies
to identify regions of the genome harbouring resistance loci.
Comparative analysis of ivermectin resistant individuals from the
MHco3/4.BC4 and MHco3/10.BC4 backcross strains with the
parental isolates can be undertaken to identify regions of the
genome derived from the MHco10(CAVR) and MHco4(WRS)
parental strains and hence harbouring resistance conferring loci.
Such analyses could include genome-wide polymorphism analysis,
RNAseq analysis (to examine expression profiles and coding-
region polymorphisms) or targeted analysis of candidate genes. It is
important to note that it is likely that the introgressed regions of
the MHco4(WRS) and MHco10(CAVR) are relatively large since
just four generations of backcrossing have been performed and
recombination will have had limited opportunity to break down
genetic linkage. Nevertheless analysis of these strains should
provide the locations of major ivermectin resistance loci in the H.
contortus genome. Further backcrossing, together with improving
genomic resources for this parasite, will provide the opportunity to
iteratively interrogate these strains to identify the genomic location
of resistance loci more accurately.
Evidence for genetic linkage of marker Hcms8a20 to a
resistance conferring loci
Of the 18 microsatellite markers that were used to monitor the
backcrossing procedure, based on the presence and absence of
strain-specific alleles, there was only one in which alleles specific to
the parental resistance strains were retained in the 4
th generation
backcross progeny for both back crosses. This was marker
Hcms8a20. Furthermore, when the FST and PCA analysis were
performed using the nine most discriminatory markers, each single
marker was iteratively excluded to check for distortions of the data
due to any effects of single markers. The only marker whose
exclusion had any discordant effect on the data was Hcms8a20
(Data not shown).The exclusion of the loci Hcms8a20 from the FST
and PCA analysis revealed that MHco3/4.BC4 and MHco3/
10.BC4 ivermectin resistant worms (survivors), the susceptible
MHco3(ISE) strain and their respective backcross strains were all
genetically indistinguishable. The inclusion of the loci Hcms8a20
into the same analysis increased the level of genetic differentiation
between these aforementioned strains of worms to the point of
statistical significance. Examination of the individual allele
frequencies for this marker confirms that the allelic profile was
more similar to the resistant parental strains than the MHco3(ISE)
parental strain (Figure 4). Indeed, a single allele, specific to the
respective resistant parental strains was retained in the two
backcross populations. These are present at relatively low
frequency (8% for allele 244 bp in MHc3/4 BC4 and 12% for
allele 248 bp in MHc3/10.B4). However, these are present at much
higher frequencies in the populations of backcross worms that
survive 0.1 mg/ml ivermectin treatment (40% for allele 244 bp in
MHc3/4 BC4 and 78% for allele 248 bp in MHc3/10.B4). It is
impossible to predict the precise changes in allele frequency one
would expect at a single locus during the backcrossing procedure,
or following drug selection, when several loci may have differing
additive contributions to the overall resistance phenotype. Howev-
er, the fact that the same locus, Hcms8a20, shows evidence of
retention of alleles specific for the parental resistant isolates in both
fourth generation backcross strains, together with the dramatic
increase in frequency of these in the phenotypically ivermectin
resistant worms (relative to the unselected backcross populations)
provides strong evidence that this locus is linked to a resistance
conferring polymorphism. The fact that different alleles appear to
be selected from the two different parental resistant strains is not
necessarily surprising. These two strains – MHco4(WRS) and
MHco10(CAVR) - are genetically divergent and originally derived
from disparate geographical regions. Consequently, it is entirely
possible that a resistance-conferring polymorphism would be
genetically linked to different haplotypes of adjacent markers. As
the H. contortus genome project progresses it will be interesting to
‘‘walk out’’ from the Hcms8a20 marker to examine additional
linked markers to define the size of the region showing evidence of
linkage disequilibrium. Furthermore, we hypothesize that addi-
tional loci contribute to the ivermectin resistant phenotype of the
MHco4(WRS) and MHco10(CAVR) parental strains. We antici-
pate that these may be identified as we iteratively interrogate the
backcross strains with larger marker panels as they become
available form the H. contortus genome sequencing project.
Similarly, the backcross strains now represent a powerful genetic
resource with which to determine if the various candidate genes
identified from other studies contribute to the ivermectin resistance
phenotype of the MHco4(WRS) or the MHco10(CAVR) strains.
In summary, we describe the introgression of resistance-
conferring loci from two independent ivermectin resistant strains
into a susceptible reference strain of H. contortus. This is a novel
approach that provides a powerful adjunct to both candidate gene
and whole genome analysis aimed at identifying anthelmintic drug
resistance loci. The continued advancement of such genetic
approaches, alongside genomic resources for H. contortus, should
allow this organisms to be used in an increasingly powerful
manner to study the genetic basis of anthelmintic resistance in
strongylid nematode parasites.
Supporting Information
Figure S1 Total worm burden of lambs. Total worm
burden of lambs following therapeutic dose (0.1 mg/kg and
0.2 mg/kg) of ivermectin against the three parental isolates and
the backcross isolates. Mean worm burden per treatment group
indicated by trend lines.
(EPS)
Figure S2 Allele frequency histograms of loci
HcmsX256 for H. contortus parental and backcross
strains. Allele frequencies resulting from individual worm
genotyping of populations of 30 single worms confirm the
Backcrossing Haemonchus contortus
PLoS Pathogens | www.plospathogens.org 8 February 2012 | Volume 8 | Issue 2 | e1002534presence of the MHco10(CAVR)-specific allele, 243 bp at the very
low level of 4.6% in the MHco3/10.BC4 strain.
(EPS)
Figure S3 Allele frequency histograms of eight loci for
H. contortus parental and backcross strains. Allele
frequencies of the microsatellite loci, Hcms27 (A), Hcms36 (B),
Hcms40 (C), Hc53265 (D), Hcmc22c03 (E), Hc22193 (F),
Hcms3086A (G) and Hc44104 (H) for parental strains (based on
genotyping 30 individual worms per strain i.e. n=30), the two 4
th
generation backcross strains (MHco3/4.BC4, n=35 and MHco3/
10.BC4, n=38) and 4
th backcross generation survivors of
ivermectin treatment (0.1 mg/kg ivermectin) (MHco3/4.BC4.sur-
vivors, n=33 and MHco3/10.BC4.survivors, n=26).
(EPS)
Table S1 Summary information for the five new H.
contortus microsatellite markers. Sequence of repeat and
primers used to amplify microsatellite loci.
(DOC)
Table S2 Treatment efficacies based on worm burden.
Arithmetic mean (6SEM) and range of H. contortus counts, sex
differentiation of worm burdens and percentage efficacies.
(DOC)
Table S3 Treatment efficacies based on faecal egg
count reduction. Arithmetic mean (6SEM) and range of faecal
egg count and percentage efficacy seven days post-treatment.
(DOC)
Table S4 Genetic profiles of backcrossed strains de-
rived from MHco4(WRS) monitored by bulk worm
microsatellite ‘‘finger-printing’’. Alleles present in the bulk
worm preparations of the parental (MHco3(ISE) and
MHco4(WRS)), F1 and backcross strains.
(XLS)
Table S5 Genetic profiles of backcrossed strains de-
rived from MHco10(CAVR) monitored by bulk worm
microsatellite ‘‘finger-printing’’. Alleles present in the bulk
worm preparations of the parental (MHco3(ISE) and MHco10(-
CAVR)), F1 and backcross strains.
(XLS)
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